KARD · Why this verdict
Why Kardigan (KARD) is rated DATA_ISSUE
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictDATA_ISSUE
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
This run's screen encountered a data outage — the upstream price feed (Alpaca/yfinance) returned no current price, meaning no trade setup, entry, target, or stop could be computed for this name. Warnings | A valid current price should be available from the upstream data feed at the next refresh, restoring the ability to compute entry, target, and stop levels. | →Stable |
| CounterA persistent data gap could reflect a delisting, halt, or ticker-symbol change rather than a transient feed issue, in which case price data may not return. | ||
The company shows quality concerns with no competitive moat and a weak Piotroski F-Score of just 2 out of 9, contributing to a low overall quality score of 1.9. Quality breakdown | The Piotroski F-Score should improve from 2/9 and the quality score should rise above the current 1.9 level over the next 12 months. | →Stable |
| CounterA weak Piotroski score is a lagging fundamental snapshot and may not reflect a clinical-stage biotech's actual value drivers, which depend on pipeline progress rather than current profitability metrics. | ||
The engine classifies this as a speculative-suitability holding specifically because it operates in the binary biotechnology industry, where outcomes hinge on discrete clinical or regulatory events rather than steady operating performance. Suitability rationale | The suitability classification should remain speculative until a de-risking event, such as trial data or a regulatory decision, clarifies the path forward over the next 12 months. | →Stable |
| CounterBinary classification alone doesn't predict direction, it only flags outcome variance, so this pillar can't be resolved by ordinary operating metrics improving. | ||
The engine explicitly found no clear trading edge for this name, reflecting the absence of a defined technical or fundamental catalyst to act on. Edge rationale | A discernible trading edge, technical or fundamental, should emerge over the next 12 months as more data becomes available. | →Stable |
| CounterA persistent absence of a clear edge could simply continue indefinitely for a thinly covered, data-sparse biotech name. | ||
This run's screen encountered a data outage — the upstream price feed (Alpaca/yfinance) returned no current price, meaning no trade setup, entry, target, or stop could be computed for this name.
→StableWarnings
- Expectation
- A valid current price should be available from the upstream data feed at the next refresh, restoring the ability to compute entry, target, and stop levels.
CounterA persistent data gap could reflect a delisting, halt, or ticker-symbol change rather than a transient feed issue, in which case price data may not return.
The company shows quality concerns with no competitive moat and a weak Piotroski F-Score of just 2 out of 9, contributing to a low overall quality score of 1.9.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should improve from 2/9 and the quality score should rise above the current 1.9 level over the next 12 months.
CounterA weak Piotroski score is a lagging fundamental snapshot and may not reflect a clinical-stage biotech's actual value drivers, which depend on pipeline progress rather than current profitability metrics.
The engine classifies this as a speculative-suitability holding specifically because it operates in the binary biotechnology industry, where outcomes hinge on discrete clinical or regulatory events rather than steady operating performance.
→StableSuitability rationale
- Expectation
- The suitability classification should remain speculative until a de-risking event, such as trial data or a regulatory decision, clarifies the path forward over the next 12 months.
CounterBinary classification alone doesn't predict direction, it only flags outcome variance, so this pillar can't be resolved by ordinary operating metrics improving.
The engine explicitly found no clear trading edge for this name, reflecting the absence of a defined technical or fundamental catalyst to act on.
→StableEdge rationale
- Expectation
- A discernible trading edge, technical or fundamental, should emerge over the next 12 months as more data becomes available.
CounterA persistent absence of a clear edge could simply continue indefinitely for a thinly covered, data-sparse biotech name.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Kardigan is currently untradeable in this screen due to a data outage on its price feed, and what data is available shows weak fundamental quality and a speculative, binary biotech profile with no identified trading edge.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.9/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 4.0 |
| Piotroski F | 2.2 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.0/10data confidence 50%Sentiment
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
Insider
5.0/10data confidence 50%Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
5.0/10data confidence 50%Risk (lower is worse)
0.3/10data confidence 20%| Component | Sub-score |
|---|---|
| debt equity | 0.3 |
Catalyst
5.0/10data confidence 50%How the verdict was assembled
Engine trigger
No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run.
Engine technical detail
verdict_path:
L0:DATA_ISSUE_NO_PRICEPassed (7)
- MOMENTUM:5.0>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:5.0<5.5 (soft — BUY_NOW allowed but watch)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
0.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The DATA_ISSUE verdict reflects clean gate clearance against Value at 5.0 and asymmetric R:R of 0.00.
The strongest dimensions are Value at 5.0, Growth at 5.0, and Momentum at 5.0; the weakest are Risk (lower is worse) at 0.3, Quality at 1.9, and Peer rank at 4.2. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1No Price Data Available
Trip ifThe current price returns as a nonzero value and stays available for more than 5 consecutive trading days.
- P2Weak Quality Piotroski Score
Trip ifPiotroski F-Score rises above 5 out of 9 from the current 2/9.
- P3Binary Biotech Speculative Classification
Trip ifAnalyst rating score rises above 7.0 from the current 5.0 following a material clinical or regulatory catalyst disclosure.
- P4No Trading Edge Identified
Trip ifA defined trading setup emerges, raising the asymmetry ratio above 1.5x from the current 0.0x.